Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
---|---|---|---|---|---|---|
2011-01-11 | Biofocus, a Galapagos Company (UK - Belgium) Ono Pharmaceutical (Japan) | novel targets in the field of autoimmune disease | Autoimmune diseases |
R&D | Autoimmune diseases | |
2011-01-11 | Alacris Theranostics (Germany) Qiagen (The Netherlands) | stake in Alacris Theranostics | ||||
2011-01-10 | Biocartis (Belgium) Janssen Pharmaceutica NV (J&J - USA) | molecular diagnostic tests | development |
Infectious diseases - CNS diseases | Development agreement | |
2011-01-09 | Silence Therapeutics (UK) miRagen Therapeutics (USA) | use of Silence’s proprietary DBTC delivery system for miRagen’s novel microRNA- (miRNA-) based therapeutics | undisclosed | R&D |
R&D agreement | |
2011-01-06 | Cell Medica (UK) Center for Cell and Gene Therapy (CAGT), Baylor College of Medicine (Houston, Texas - USA) | cell-based treatment for cancers associated with the oncogenic Epstein Barr virus (EBV) | EBV-associated lymphoma and nasopharyngeal carcinoma (NPC) | R&D |
Cancer - Oncology | R&D agreement |
2011-01-06 | Spirogen (UK) - Genentech a member of the Roche Group (USA-Switzerland) | antibody drug conjugates (ADCs) as potential anticancer agents | cancer | R&D |
Cancer - Oncology | Licensing agreement |
2011-01-05 | arGEN-X (The Netherlands) Eli Lilly (USA) | therapeutic antibodies | R&D |
Cancer - Oncology | R&D agreement | |
2011-01-05 | Transgene (France) Beckman Coulter (USA) | companion test to measure the level of activated Natural Killer (“aNK”) cells in order to select patients to be treated with TG4010 (MVA-MUC1-IL2 immunotherapy candidate, is about to enter into a pivotalPhase IIb/III clinical trial for the treatment of Non-Small Cell Lung Cancer) | non small cell lung cancer | R&D |
Cancer Oncology | R&D agreement |
2011-01-05 | Selexis (Switzerland) Neogenix Oncology (USA) | production cell line expressing Neogenix NPC-1C | licensing |
Licensing agreement | ||
2011-01-05 | to-BBB (The Netherlands) Synageva BioPharma (USA) | transporting therapeutic proteins across the blood-brain barrier into the central nervous system | R&D |
Rare diseases | R&D agreement | |
2011-01-04 | Argenta (Galapagos subsidiary – UK Belgium) Dr. Reddy's Laboratories (India) | pain-inflammation | development |
CNS diseases - Inflammatory diseases | Development agreement | |
2011-01-04 | Kinaxo Biotechnology (Germany) AstraZeneca (UK) | drug targets | R&D |
Cancer Oncology | R&D agreement | |
2011-01-04 | Santaris Pharma (Denmark) Pfizer (USA - NY) | RNA-targeted medicines using Santaris Pharma A/S Locked Nucleic Acid (LNA) Drug Platform. | R&D |
R&D agreement | ||
2011-01-04 | Servier (France) Xoma (USA - CA) | gevokizumab (Xoma 052) | Behcet\'s uveitis, inflammatory diseases, cancer | Cancer - Oncology - Inflammatory diseases - Rare diseases | Development agreement | |
2011-01-03 | Mercator Therapeutics (USA) Pepscan Therapeutics (The Netherlands) | optimization of homing peptides | tumors | R&D |
Cancer - Oncology | R&D agreement |
2010-01-10 | Bind Biosciences (USA - MA) | nomination |
Nomination | |||
2010-01-06 | Amsterdam Molecular Therapeutics (The Netherlands) - consortium led by Institut Pasteur (France) | adeno-associated viral 5 (AAV5) gene therapy | Sanfilippo B (rare autosomal recessive lysosomal storage disease, which manifests in young children) | Development |
Rare diseases | Development agreement |
0201-10-06 | Horizon Discovery (UK) Haplogen Genomics (Austria) | CRISPR/Cas9 human haploid cell line generation service and human haploid knock-out cell lines catalog | distribution |
Technology - Services | Distribution agreement | |
0000-00-00 | Ipsen (France) Oncodesign (France) | new therapeutic agents against the LRRK2 Parkinson's disease target | Parkinson's disease | R&D - research | Neurodegenerative diseases - CNS diseases | Termination of an agreement |
0000-00-00 | ViiV Healthcare (UK - USA) the Medicines Patent Pool | Tivicay® (dolutegravir) | HIV1-infection | collaboration |
Infectious diseases | Collaboration agreement |